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A novel approach to personalizing postgrafting immunosuppression in hematopoietic cell transplantation
(HCT) recipients is evaluating inosine monophosphate dehydrogenase (IMPDH) activity as a drug-speciﬁc
biomarker of mycophenolic acid (MPA)-induced immunosuppression. This prospective study evaluated
total MPA, unbound MPA, and total MPA glucuronide plasma concentrations and IMPDH activity in peripheral
blood mononuclear cells (PMNCs) at 5 time points after the morning dose of oral mycophenolate mo-
fetil (MMF) on day þ21 in 56 nonmyeloablative HCT recipients. Substantial interpatient variability in
pharmacokinetics and pharmacodynamics was observed and accurately characterized by the population
pharmacokinetic-dynamic model. IMPDH activity decreased with increasing MPA plasma concentration, with
maximum inhibition coinciding with maximum MPA concentration in most patients. The overall relationship
between MPA concentration and IMPDH activity was described by a direct inhibitory maximum effect model
with an IC50 of 3.23 mg/L total MPA and 57.3 ng/mL unbound MPA. The day þ21 IMPDH area under the effect
curve (AUEC) was associated with cytomegalovirus reactivation, nonrelapse mortality, and overall mortality.
In conclusion, a pharmacokinetic-dynamic model was developed that relates plasma MPA concentrations
with PMNC IMPDH activity after an MMF dose in HCT recipients. Future studies should validate this model
and conﬁrm that day þ21 IMPDH AUEC is a predictive biomarker.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION this interindividual variability (IIV). MMF is rapidly hydrolyzed
The availability of allogeneic hematopoietic cell trans-
plantation (HCT) has expanded with the development of
lower dose nonmyeloablative conditioning regimens, which
depend on achieving a delicate balance between recipient
and donor cells to obtain immunosuppression of the re-
cipient, optimal antitumor effect, and minimal toxicity [1].
Nonmyeloablative HCT recipients often receive mycophe-
nolate mofetil (MMF) and a calcineurin inhibitor (cyclo-
sporine or tacrolimus) as postgrafting immunosuppression,
which aims to facilitate allogeneic engraftment and control
graft-versus-host disease (GVHD) [2,3].
There is considerable variability in the clinical outcomes of
these patients. Some interpatient variability in clinical out-
comes could, in part, reﬂect differences in each recipient’s
sensitivity to MMF. The pharmacokinetics and drug-speciﬁc
pharmacodynamics of mycophenolic acid (MPA), the thera-
peutically active metabolite of MMF, are potential sources ofedgments on page 1128.
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14.03.032to MPA in the gastrointestinal tract. After rapid absorption,
MPA undergoes hepatic metabolism by various UDP-glucur-
onosyltransferase isoenzymes to form MPA glucuronide (total
MPAG) [4]. After oralMMFadministration, there is considerable
between-patient variability in total and unbound MPA area
under the concentration-time curves (AUCs) [5,6]. The available
pharmacodynamic data in allogeneic HCT recipients suggest a
relationship between MPA AUC and clinical outcomes [7].
Although some HCT centers have proposed personalizing MMF
doses based on MPA AUC [8], there is an ongoing debate
regarding the beneﬁts of such therapeutic drug monitoring in
solid organ transplantation [9].
MPA is a selective, reversible, and noncompetitive in-
hibitor of inosine monophosphate dehydrogenase (IMPDH)
[10]. IMPDH is the rate-limiting enzyme involved in the de
novo synthesis of guanosine nucleotides; IMPDH catalyzes
the oxidation of inosine 50-monophosphate to xanthosine
50-monophosphate (XMP) by a nicotinamide adenine
dinucleotide positiveedependent reaction [11]. Character-
izing the pharmacodynamic relationship between MPA and
IMPDH activity is critical to understanding the potential
beneﬁt of alternative MMF dosing strategies in non-
myeloablative HCT recipients. Thus, we sought to charac-
terize the pharmacokinetic-dynamic relationship betweenTransplantation.
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IMPDH activity in peripheral blood mononuclear cells
(PMNCs) in nonmyeloblative HCT recipients receiving MMF
as postgrafting immunosuppression.METHODS
Patient Characteristics
Between November 2008 and February 2012, 105 patients participated
in a prospective ancillary biomarker study in nonmyeloablative allogeneic
HCT recipients. Study participation inﬂuenced neither the conditioning
regimen nor postgrafting immunosuppression. Patients (age > 18 years)
receiving ﬂudarabine monophosphate (Fludara; Berlex, Montville, NJ) and
total body irradiation conditioning, a related or unrelated donor granulocyte
colony-stimulating factoremobilized peripheral blood mononuclear cell
(G-PBMC) graft, and postgrafting immuosuppression with a calcineurin in-
hibitor (cyclosporine or tacrolimus) and MMF were eligible for recruitment
in this study. One participant received both G-PBMCs and bone marrow
because of inadequate G-PBMC yield from the donor’s apheresis. The choice
and kinetics-based dose targeting of the calcineurin inhibitor were deter-
mined by the HCT protocol. In addition to cyclosporine or tacrolimus, some
participants also received sirolimus as part of their postgrafting
immunosuppression.
Exclusion criteria included diagnosis of an immunodeﬁciency disorder
or scheduled to receive immunosuppression in addition to ﬂudarabine/total
body irradiation (eg, alemtuzumab, thymoglobulin) during HCT condition-
ing to day þ28 after graft infusion. This protocol was approved by the
Institutional Review Board at the Fred Hutchinson Cancer Research Center
(FHCRC Protocol 1980, Clinicaltrials.gov NCT00764829). Written informed
consent was obtained from all patients before study participation.
The MMF dose and administration frequency were speciﬁed by the HCT
protocol. MMF doses were based on bodyweight and rounded to the nearest
250-mg dose, as previously described [6]. MMF doses were not adjusted
based on MPA plasma concentrations or IMPDH determinations.
This cohort was divided into 2 separate datasets, the development
dataset and the validation dataset. The development dataset was used to
develop the pharmacokinetic/dynamic model relating plasma MPA con-
centrations with PMNC IMPDH activity and to validate our previous popu-
lation pharmacokinetic model [5,6]. The validation dataset was used to
validate the pharmacokinetic/dynamic model relating plasma MPA con-
centrations and PMNC IMPDH. The patient characteristics of the develop-
ment and validation datasets are shown in Table 1.Table 1
Participant Characteristics
Development Datase
Number of participants 34
Female/male gender (% male) 14/20 (59%)
Recipients’ ages, yr 63 (28-72)
Adjusted ideal body weight, kg 70.6 (44.3-88.8)
Height, cm 172 (149-184)
Body surface area, m2 1.96 (1.40-2.60)
Donor type, related/unrelated (% related) 6/28 (18%)
Female donor to male recipient 7 (21%)
Kahl relapse risk
Low 13 (38%)
Standard 13 (38%)
High 8 (24%)
Covariates associated with MPA clearance
Concomitant calcineurin inhibitory
Cyclosporine 25 (74%)
Tacrolimus 9 (26%)
Serum creatinine (mg/dL) 1.1 (.6-2.0)
Serum albumin (g/dL) 3.4 (2.1-4.2)
Pharmacokinetic sampling around morning MMF dose on day þ21z
Before and 1, 2, 2.5, 6 hx 29 (85%)
Before and 1.25, 2, 3, 4 hk 5 (15%)
Day þ28 donor T cell chimerism 85% (35-100)
Categorical data presented as number (percentage) of participants meeting stated
* Three patients (1 related, 2 unrelated donor) had antigen-level mismatch.
y Concomitant sirolimus in 8 cyclosporine and 3 tacrolimus patients (see Patien
z Modiﬁed to improve patient adherence (see Sample Collection in Methods).
x November 2008 to March 2011.
k April 2011 to February 2012.Sample Collection
Peripheral blood samples (8 mL drawn into EDTA vacutainers,
Supplemental Figure 1) were obtained on day þ21. The total MPA, unbound
MPA, and total MPAG plasma concentrations and IMPDH activity in PMNCs
were quantitated in each sample. All assays were performed on each of the
samples. Of the 56 AUCs, 2 were collected on day þ19, 17 on day þ20, 32 on
dayþ21, 3 on dayþ22,1 on dayþ23, and 1 on dayþ25. Samples were drawn
before and 1, 2, 2.5, and 6 hours after oral MMF for 29 patients (November
2008 to March 2011; development and validation cohorts) and before and
1.25, 2, 3, and 4 hours after oral MMF for 27 patients (April 2011 to February
2012, validation cohort). These patients were primarily treated in the
ambulatory clinic, and therefore limited sampling schedules were used to
maximize compliance. From November 2008 to March 2011, compliance for
pharmacokinetic samples was 63% (41 of 65 participants); this decreased to
50% (6 of 12 participants) when participants were paid per AUC obtained. In
April 2011, the sampling schedule was shortened to 4 hours after the oral
MMF dose based on a prior analysis [6]. With this change, complaince
improved to 76% (26 of 34 participants). In 50 of 56 participants, all 5
samples were collected. Among the remaining participants, 2 had 1 sample
collected, 1 had 3 samples collected, 2 had 4 samples collected, and 1 had 6
samples collected. IMPDH activity on day þ2 after HCT was planned; this
could not be conducted, however, due to myelosuppression resulting from
the conditioning regimen.
Table 1 lists the participant characteristics, including biochemistry
values and concomitant medications associated with MPA pharmacokinetic
parameters. Our previous population pharmacokinetic model after intra-
venous or oral MMF administration indicated that MPA clearance was
signiﬁcantly increased (by 33.8%) with concomitant cyclosporine and
negatively correlated with albumin concentration [6].
Reagents and Chemicals
All nucleotides used as substrates for the enzymatic assay or as chro-
matographic standards were obtained from Sigma (St. Louis, MO). Nicotin-
amide adenine dinucleotide was also purchased from Sigma. Acetonitrile,
ammonium acetate, methanol, sodium hydroxide, sodium phosphate
monobasic, ammonium acetate, ammonium hydroxide, and potassium
chloride were all purchased from Thermo Fisher (Waltham, MA). Dulbecco’s
PBS was purchased from Invitrogen (Grand Island, NY). Ficoll Hypaque so-
lution (density 1.077 g/mL) was obtained from GE Healthcare (Uppsala,
Sweden).
Quantitation of MPA and Total MPAG
Each plasma sample was analyzed for total MPA, unbound MPA, and
total MPAG plasma concentrations using reverse phase HPLC with masst Validation Dataset Overall
22 56
7/15 (68%) 21/35 (63%)
58 (26-73) 62 (26-73)
71.2 (44.4-93.4) 70.7 (44.3-93.4)
173 (147-194) 172 (147-194)
1.95 (1.50-2.47) 1.95 (1.40-2.60)
5/17 (23%)* 11/45 (20%)
8 (36%) 15 (27%)
6 (27%) 19 (34%)
13 (59%) 26 (46%)
3 (14%) 11 (20%)
18 (82%) 43 (77%)
4 (18%) 13 (23%)
1.2 (.7-2.2) 1.1 (.6-2.2)
3.5 (2.4-4.1) 3.4 (2.1-4.2)
0 29 (52%)
22 (100%) 27 (48%)
95% (61-100) 89% (35-100)
criteria; continuous data presented as median (min-max).
t Characteristics in Methods).
Figure 1. Final pharmacokinetic model characterizing total MPA, unbound
MPA, and total MPAG concentrations following oral MMF administration. tlag,
lag time; GI, gastrointestinal tract; ka, ﬁrst-order absorption rate constant; fu,
fraction unbound of MPA; Vc, volume of central compartment of total MPA;
Q, intercompartment clearance of total MPA; Vp, volume of peripheral
compartment of total MPA; CLMPA, clearance of total MPA; CLMPAG, clearance of
total MPAG; Vm, volume of central compartment of total MPAG; k41, ﬁrst-order
rate constant of EHC.
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plasma samples (100 mL) with the internal standard (20 mL MPA-d3 andMPA
b-D-glucuronide-d3) were combined with 50 mL methanol and 1000 mL
acetonitrile, vortexed, and subsequently centrifuged. The supernatant (1 mL)
was injected onto a light chromatography (LC)/MS running a gradient of
2.0 mM ammonium formate (pH 3.3) and acetonitrile through an Agilent
C18 column (2.1mm 150mm 5 mm; Agilent Technologies, Palo Alto, CA).
Monitored ions includedm/z 321 for the (MþHþ) ion of MPA,m/z 324 for the
(MþHþ) ion of MPA-d3 (internal standard),m/z 495.2 for the (MþHþ) ion of
total MPAG, and m/z 498.1 for the (MþHþ) ion of total MPAG-d3 (internal
standard). The dynamic range was .3 to 15.5 mg/L for MPA and .21.5 to
215 mg/L for total MPAG. The interday coefﬁcient of variation was less
than 10.7%.
Unbound MPA plasma concentrations were determined by equilibrium
dialysis using Pierce rapid equilibrium dialysis devices (Thermo Fisher).
After incubation and processing of plasma samples according to Pierce rapid
equilibrium dialysis manufacturer instructions, samples were analyzed
using LC/MS as above with slight modiﬁcations (ie, mobile phase was an
isocratic mixture of 55% 2.0 mM ammonium formate [pH 3.3] and 45%
acetonitrile, with a total run time was 5 minutes). The percentage of un-
bound (free) MPA was calculated as follows: unbound MPA ¼ 100  (1-
bound MPA).
Isolation of Human PMNCs and IMPDH Activity Assay
PMNCs were isolated within 6 hours of collection by diluting blood in
PBS at a 1:1 v:v ratio and subsequently layering on top of Ficoll as previously
described [12]. In brief, PMNCs were collected, diluted to 10 mL with PBS to
wash, and centrifuged. The cell counts were quantitated using a Horiba
Diagnostics ABX Micro 60 (Irving, CA), and distilled water was added to the
supernatant to adjust the cell concentration to .5  106 cells/mL lysate. This
PMNC count was used to standardize the IMPDH activity measurement.
After storage at 80C, the IMPDH activity was determined from the con-
version of inosine monophosphate to XMP according to procedures adapted
from Glander et al. [13] and Daxecker et al. [14]. The incubation reaction
mixture included NaH2PO4, KCl, inosinemonophosphate (.8mL of 6.0 mmol/
L) and nicotinamide adenine dinucleotide (.8 mL of 4.5 mmol/L, made fresh
each day). The incubation reaction was started via the addition of the
reaction mixture to 50 mL prewarmed cell lysate (standard concentration of
.5  106 cells/mL).
For each incubation, the enzymatic reaction was terminated after
2.5 hours of incubation by the addition of methanol followed by in-
ternal standard (8-bromo adenosine 50-monophosphate), processed, and
injected on the LC/MS running a gradient of .1 M ammonium acetate (pH
8.5) and acetonitrile through a Thermo Scientiﬁc Hypercarb column
(2.0 mm  100 mm  5 mm, part no. 35005-102130; Thermo Scientiﬁc,
Bellefonte, PA). An Agilent G1946D mass selective detection (Agilent
Technologies) atmospheric pressure ionization-electrospray in positive
ion mode was used. The mass selective detection was run in the selected
ion monitoring mode. Monitored ions included m/z 365 for the (MþHþ)
ion of XMP,m/z 348 for the (MþHþ) ion of adenosine monophosphate, and
m/z 426 for the (MþHþ) ion of 8-bromo adenosine 50-monophosphate, the
internal standard. Typical retention times were 4.3 minutes for XMP,
5.1 minutes for inosine monophosphate, and 7.0 minutes for 8-bromo
adenosine 50-monophosphate. The limit of quantiﬁcation (signal-to-
noise ratio > 60 and coefﬁcient of variation < 2%) was 58 pmol.
A quality control pooled lysate obtained from the PMNCs of healthy
subjects was run in triplicate with every incubation. The coefﬁcient of
variation for the control lysate was 6.2% over 39 incubations. Each PMNC
sample was run in triplicate; the average of the triplicates is reported as the
IMPDH activity. IMPDH activity is standardized to the ex vivo PMNC count
determined after Ficoll isolation and expressed as pmol XMP/106 cells/h.
MPA Population Pharmacokinetic-Dynamic Analysis
Pharmacokinetic (total MPA, unbound MPA, and total MPAG plasma
concentrations) and pharmacodynamic (XMP formation in PMNCs to pro-
vide IMPDH activity) data were available at each concentration time point.
The pharmacokinetic-dynamic models were developed in a sequential
manner: the pharmacokinetic model was developed ﬁrst, then each par-
ticipant’s pharmacokinetic parameters were ﬁxed for the creation of the
pharmacodynamic model.
The initial pharmacokinetic model of Li et al. [6], which was developed
in 402 HCT recipients, was modiﬁed to include total MPAG (as described by
Musuamba et al. [15]) and unbound MPA concentrations. Brieﬂy, total MPA
pharmacokinetics was described using a 2-compartmental model with ﬁrst-
order elimination and ﬁrst-order absorption with a lag time (Figure 1).
The model was parameterized as clearance (CL), volume of the central
compartment (Vc), volume of the peripheral compartment (Vp), and inter-
compartment clearance (Q). Total MPAG pharmacokinetics was describedusing a 1-compartmental model with ﬁrst-order elimination. It was
assumed that MPA is metabolized to total MPAG by a ﬁrst-order process and
that 100% of MPA is converted to total MPAG because urinary MPA data were
not available. Collection of urinary excretion data was not possible because
participants were treated in the ambulatory clinic. Therefore, total MPAG CL
and Vd are apparent clearance and volume of distribution (ie, CL/fm and V/
fm). Enterohepatic recirculation (EHC) of total MPAG was represented as a
ﬁrst-order process between the total MPAG central compartment and the
gastrointestinal tract. Unbound MPA concentrations were modeled as
[MPAunbound] ¼ [MPAtotal]  fu, with [MPAunbound], [MPAtotal], and fu repre-
senting unbound MPA concentration, total MPA concentration, and the
unbound fraction, respectively.
We also sought to validate the covariate effect of the calcineurin in-
hibitor (cyclosporine or tacrolimus) on MPA clearance [5,6]. MPA clearance
was eventually deﬁned by the following equation:
MPA CL ¼ 24:2

body weight
70
:75


albumin
3:4
-:686
 ð1þ :338 CSPÞ
(Eq. 1)
with body weight in kg, albumin in g/dL, and CSP ¼ 1 for cyclosporine and
0 for tacrolimus.
The Bayesian total MPA AUC0-8h of 27 participants who received MMF
every 8 hours was calculated. The AUCs of patients receiving concomitant
tacrolimus were compared with those of patients taking cyclosporine. In
addition, this simulation was executed using population mean parameter
estimates to compare total MPA AUC0-12h in patients receiving either
concomitant cyclosporine or tacrolimus. Both Bayesian estimations and
simulations were performed using NONMEM VII (Icon Development Solu-
tions, LLC, Ellicott City, MD).
Subsequent to ﬁnalization of the population pharmacokinetic model,
the relationship between MPA concentrations and IMPDH activity was ex-
plored graphically and modeled using an inhibitory maximum effect model:
E ¼ E0 
 
1e
Imax  Cgp
ICg50 þ Cgp
!
(Eq. 2)
with E0 as baseline IMPDH activity (minimal inhibition), Imax as maximal
IMPDH inhibition, Cp as the MPA plasma concentration, IC50 as the MPA
concentration that causes 50% of maximal IMPDH inhibition, and g as the Hill
coefﬁcient that governs the slopeofMPAconcentrationversus IMPDHactivity.
Population pharmacokinetic-dynamic analysis was performed using
nonlinear mixed effects modeling (NONMEM VII .1.0). The Monte Carlo
Important Sampling expectation maximization method was used
throughout the modeling process. Pharmacokinetic models were simulta-
neously ﬁtted to total MPA, unbound MPA, and total MPAG plasma con-
centrations. MMF dose and total MPAG concentration were multiplied by
H. Li et al. / Biol Blood Marrow Transplant 20 (2014) 1121e11291124.739 and .594, respectively, to convert these values to their equivalent MPA
values [16]. Clearance and volume of distribution were allometrically scaled
to body weight with exponents ﬁxed to .75 and 1, respectively. Between-
subject variability was modeled using an exponential error model. Phar-
macokinetic data were log-transformed, and an additive error model was
applied to describe residual error. A proportional error model was used for
pharmacodynamic residual error.
Stepwise forward selection and backward elimination, based on the
likelihood ratio test and a prespeciﬁed alpha level, were applied across the
base, intermediate, and ﬁnal models [5]. A covariate was included in the
intermediate model when a decrease of at least 6.6 in the objective function
value (P< .01) occurred. A covariatewas retained in the ﬁnal model when an
increase of at least 10.8 in objective function value (P< .001) occurred when
this covariate was removed. The tested covariates included age, body
surface area, serum albumin, blood urea nitrogen, serum creatinine, creat-
inine clearance, alkaline phosphatase, alanine aminotransferase, aspartate
aminotransferase, lactate dehydrogenase, total bilirubin, and direct bili-
rubin. All biochemistry values were obtained within 7 days before the
pharmacokinetic-dynamic sampling.
Model Validation
The pharmacokinetic-dynamic model was validated internally and
externally. Goodness-of-ﬁt and visual predictive check plots were used for
internal validation. Goodness-of-ﬁt plots included observed versus pre-
dicted concentrations as well as conditional weighted residuals versus
model predictions and time after dose. For visual predictive check plots, 500
datasets were simulated from parameter estimates of the ﬁnal model, and
the 5th, 50th, and 95th percentiles of simulated data were compared with
observed data.
External validation was carried out using 2 methods: predicting
observed pharmacokinetic-dynamic data in the validation dataset (n ¼ 22
participants) and comparing results of Monte Carlo simulations to the
observed data. Using the population model developed from the develop-
ment dataset, predicted concentrations (both population and Bayesian
predictions) were calculated for each participant in the validation dataset,
using the known MMF dosing history and available pharmacokinetic sam-
pling times. Predictions were obtained by setting POSTHOC and
MAXEVAL ¼ 0 options in the NONMEM $ESTIMATION command. Bias in
model prediction was assessed by calculating the percent mean prediction
error (MPE%) as follows:
MPE%ðPREDÞ ¼
 
1
N
Xn
i¼1
PREDeOBS
OBS
!
 100 (Eq. 3)
MPE%ðIPREÞ ¼
 
1
N
Xn
i¼1
IPRE OBS
OBS
!
 100 (Eq. 4)
where PRED and IPRE are population prediction and individual (Bayesian)
predictions, respectively, and OBS represents the observed data of the par-
ticipants in the validation dataset. The Monte Carlo simulation approach
generated a total of 100 studies of 22 participants. Simulations combined
estimated pharmacokinetic-dynamic parameters from the development
dataset with participant characteristics, dosing, and sampling information
from the validation dataset. The median, 5th, and 95th percentiles of
simulated data were plotted alongside the corresponding median, 5th, and
95th percentiles of observed data. This simulation was performed in NON-
MEM VII. Plots and statistical analysis were performed in S-PLUS 8.0
(Insightful Corp, Seattle, WA) or the open-source statistical software R
(version 2.10.0; R Foundation for Statistical Computing, Vienna, Austria;
available at: http://www.R-project.org).
Clinical Outcomes
The area under the effectetime curve (AUEC, pmol  106 cells) for
IMPDH activity was calculated for the statistical analysis with clinical out-
comes. Speciﬁcally, the participant’s predose value for IMPDH activity was
considered as baseline, and then the area below the baseline was calculated
using noncompartmental analysis to provide the AUEC. Because the latest
assessment of IMPDH AUEC occurred on day þ25, analysis of clinical out-
comes was restricted to events taking place on day þ26 or later.
Clinical outcomes of interest were toxicity to MMF (ie, cytomegalovirus
[CMV] reactivation), efﬁcacy of MMF (ie, day þ28 donor T cell chimerism,
acute and chronic GVHD), and overall HCT outcomes (ie, relapse, nonrelapse
mortality, and overall survival). For day þ28 T cell chimerism: 9% had donor
chimerism less than 50% and 32% had donor chimerism less than 75%. The
median for day þ28 donor T cell chimerism was 89% (range, 35% to 100%).
Only 1 participant experienced graft rejection, so this was not evaluated.
Of the 56 participants, 12 (21%) were CMV positive with a CMV-positive
donor, 21 (38%) were CMV positivewith a CMV-negative donor, 8 (14%) wereCMV negative with a CMV-positive donor, and 15 (27%) were CMV negative
with a CMV-negative donor. When either the donor or recipient was CMV
positive, the CMV antigenemia assay to detect CMV pp65 antigen was per-
formed on a weekly basis for the ﬁrst 3 months after HCT. Twenty-two
participants experienced CMV reactivation post-transplant. Acute GVHD
was graded as previously described [17]. Hematological diseases were
classiﬁed as low, standard, or high risk of relapse per the Kahl criteria to
evaluate relapse rate in a consistentmanner [18].We deﬁned disease relapse
or disease progression as disease recurrence after complete remission or
progression of persistent disease. Clinical endpoints were measured to the
time of last clinical follow-up. The median time to last clinical follow-up was
1.4 years (range, .3 to 3.3 years).
Statistical Analysis
IMPDH AUEC was treated as a ﬁxed covariate. Cumulative incidence
curves for acute GVHD were estimated using methods previously described
[19]. Cox regression analysis was used to model the impact of IMPDH AUEC
on time-to-event endpoints. Death and relapse were treated as competing
risks for analysis of acute and chronic GVHD. Relapse was treated as a
competing risk for the analysis of nonrelapsemortality. The effects of IMPDH
AUEC on hazard ratios were expressed as the effect per doubling of IMPDH
AUEC. All reported P values are 2-sided, and those estimated from regression
models are derived from the Wald test. No adjustments were made for
multiple comparisons.
RESULTS
Patient characteristics are summarized in Table 1. The
dose, administration route, and administration frequency of
MMF were determined by the participant’s HCT transplant
protocol.
Population Pharmacokinetic Model
A total of 167 pharmacokinetic samples (total MPA, un-
bound MPA, and total MPAG) was used for population
pharmacokinetic model building. A previously developed
MPA pharmacokinetic model was modiﬁed to include total
MPAG EHC (Figure 1). Total MPAG was assumed to be
excreted to the gastrointestinal tract by a continuous ﬁrst-
order process. It was estimated that 29.5% of MPA (ie, EHC
%¼ k41/(k41þ CLTOTAL MPAG/Vm)) underwent EHC. Data ﬁtting
was signiﬁcantly improved when EHC was only integrated
with concomitant tacrolimus. The current dataset did not
support a more physiologically based EHC model [20]. Of
note, the lag time could not be estimated for each participant
because his or her food intake was not available. The popu-
lation mean of lag time was ﬁxed to a previous estimate [5]
because the sampling schedule was inadequate to estimate
this parameter. Because of convolution of the absorption and
distribution phases of MPA and the absence of intravenous
data, Vp could not be identiﬁed and was ﬁxed to a previously
determined value [5]. Pharmacokinetic parameters were
well estimated, as shown in Table 2. The visual predictive
checks and the time courses of total MPA concentration,
unbound MPA concentration, and total MPAG concentration
are shown in Supplemental Figure 2.
Covariate analysis identiﬁed serum creatinine as a signiﬁ-
cant covariate of total MPAG CL. Inclusion of serum creatinine
in the model resulted in a 24-unit decrease in objective
function value and a 9.7% decrease in IIV of total MPAG CL. The
ﬁnal pharmacokinetic model included both cyclosporine and
serum creatinine as model covariates. Goodness-of-ﬁt plots
are presented in Supplemental Figure 3.
Cyclosporine inhibits multidrug resistance-associated
protein 2emediated EHC of total MPAG and thus results in
decreased MPA AUC and increased MPA clearance
(Supplemental Figure 4). Median total MPA AUC0-8h was
increased by 33% in participants receiving concomitant
tacrolimus. In addition, simulations using population means
demonstrated that the MPA AUC0-12h in participants taking
Table 2
Population Pharmacokinetic Analysis for Total MPA, Unbound MPA and Total MPAG Plasma Concentrations
Pharmacokinetic Model Parameter Estimates (RSE%)
Parameter Explanation Base Model Final Model
ka (h1) First-order rate constant representing both formation and absorption process .913 (11.7) .916 (12.4)
Tlag (h) Lag time of oral absorption .228 FIXED .228 (21) FIXED
CLMPA (L/h/70 kg)* Clearance of total MPA 31.4 (5.6) 31.4 (5.7)
CLTOTAL MPAG (L/h/70 kg)y Clearance of total MPAG 1.29 (7.2) 1.32 (5.9)
QMPA (L/h/70 kg) Intercompartmental clearance of total MPA 11.6 (29.8) 11.5 (27.7)
k41 (L/h/70 kg) First-order rate constant representing total MPAG EHC .0503 (45.3) .0558 (44.1)
Vc (L/70 kg) Volume of central compartment of total MPA 25.3 (13.0) 26.5 (12.9)
Vp (L/70 kg) Volume of peripheral compartment of total MPA 247 (21) FIXED 247 (21) FIXED
Vm/fm (L/70 kg) Volume of central compartment of total MPAG 9.91 (8.9) 9.91 (8.8)
fu (%) Fraction unbound of MPA 1.76 (2.6) 1.76 (2.7)
qcreatinine
y Power coefﬁcient of creatinine covariate effect on total MPAG clearance Not estimated (NE) e.919 (19.5)
Interindividual variabilityz
ka (CV%) 55.0 (35.1) 55.0 (42.2)
Tlag (CV%) 133.4 (24.7) 132.7 (25.9)
CLMPA (CV%) 38.2 (21.2) 38.5 (21.4)
CLTOTAL MPAG (CV%) 53.7 (18.5) 44.0 (18.5)
Q (CV%) 162.8 (35.3) 161.2 (29.5)
k41 (CV%) 118.3 (70.7) 110.5 (65.7)
Vc (CV%) 47.1 (46.8) 47.0 (79.6)
Vp (CV%) 84.2 (49.5) 86.4 (109.2)
Vm/fm (CV%) 44.4 (34.3) 45.1 (32.1)
fu (CV%) 14.9 (31.8) 15.0 (33.0)
Residual variabilityx
Total MPA .20 (11.3) .20 (11.8)
Unbound MPA .20 (11.2) .20 (11.8)
Total MPAG .09 (11.9) .09 (12.1)
CV indicates coefﬁcient of variation; RSE, relative standard error; Tlag, lag time.
* Typical CL values were calculated as described in Eq. 1. Body weight calculations described in Patient Characteristics in Methods.
y CLTOTAL MPAG, CLpop  (serum creatinine/1.12)e.919.
z Bioavailability was ﬁxed to 1.
x Additive residual error was on a natural logarithmic-scale.
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taking cyclosporine. Overall, these results conﬁrmed our
previous ﬁndings [6] and can be considered as an external
validation for Eq. 1 where MPA CL is increased by 33.8% with
concomitant cyclosporine.
Population Pharmacokinetic-Dynamic Model
For the pharmacodynamic analysis, 267 PMNC samples
were available for ex vivo IMPDH activity quantitation. Of
these, 263 samples had 3 replicates for IMPDH activity and 4
samples had 2 replicates. Within-sample variability was
calculated by dividing the lowest XMP formation rate by the
highest rate within each sample (ie, minimum/maximum).
Thewithin-sample variability ranged from 74% to 100%. Most
replicates (257, 96%) had within-sample variability greater
than 90%. For pharmacodynamic model building, there were
166 IMPDH activity measurements in the development
dataset and 101 IMPDH activity measurements for the vali-
dation dataset.
The concentration-response relationships between MPA
concentration (either total or unbound) and IMPDH activity
are shown in Figure 2. IMPDH activity was inversely related
to total MPA (Figure 2A) and unbound MPA (Figure 2B)
concentrations. The greatest level of inhibition was associ-
ated with the greatest MPA concentration, after which
IMPDH activity returned to near predose values. This asso-
ciation is shown for the entire population (Figure 2C) as
mean plus standard deviation and also using each partici-
pant’s predose MPA concentration and IMPDH activity as
their own controls (Figure 2D). Maximum inhibition coin-
cided with maximum MPA concentration, indicating a direct
effect relationship.When analyzing all 267 pharmacokinetic-
dynamic data points in the development dataset, the MPAconcentration e IMPDH activity relationship could be well
described by an inhibitory direct effect Emax model (Eq. 2).
The ﬁnal model-based IC50 estimate was 3.23 mg/L (relative
standard error 10.7%; IIV 53.1%CV) for total MPA and 57.3 ng/
mL (relative standard error 11.2%; IIV 56.3%CV) for unbound
MPA. Maximum inhibition could not be estimated from the
observed data and was therefore ﬁxed to 1. The Hill coefﬁ-
cient was estimated to be close to 1 and was ﬁxed to 1 in the
ﬁnal parameter estimation. Table 3 summarizes the esti-
mated and ﬁxed population pharmacodynamic parameters.
The ﬁnal pharmacodynamic model did not include any of
the available covariates. Age was negatively correlated with
E0, with a Pearson correlation of .25 (P¼ .06). Inclusion of age
as a model covariate did not result in a signiﬁcant improve-
ment in model ﬁtting, and age was thus not included in the
ﬁnal model. Notably, the calcineurin inhibitor and graft
source (ie, related versus unrelated donor) did not affect the
IC50 or E0 (Supplemental Figure 5).
The ﬁnal pharmacokinetic-dynamic parameter estimates
were updated using a combination of both the model-
building and validation datasets (Tables 2 and 3). Both
visual predictive check and goodness-of-ﬁt plots demon-
strated that the ﬁnal model precisely described the observed
pharmacokinetic and pharmacodynamic data (Supplemental
Figures 2 and 3).
Validation of the Population Pharmacokinetic-Dynamic
Model
The participant characteristics were similar between the
model-building and validation datasets (Table 1). Two
methods were applied to the validation dataset to externally
corroborate the developed population pharmacokinetic-
dynamic model. The results from both methods
Table 3
Population Pharmacodynamics Parameters Describing Relationship be-
tween Total or Unbound MPA Concentrations and IMPDH Activity on
Day þ21 in Nonmyeloablative HCT Recipients Taking MMF
Parameter Explanation Estimates* (RSE%)y for
IMPDH Activity (pmol
XMP/106 cells/h)
E0 Baseline IMPDH activity
(immediately before
day þ21 MMF dose)
1370 (5.6)
Total MPA
(mg/L)
Unbound MPA
(ng/mL)
IC50 MPA concentration causing
50% maximal inhibition
3.23 (10.7) 57.3 (11.2)
IIV_E0 (CV%) Interindividual variability
of E0
27.6 (30.8) 27.3 (31.4)
IIV_IC50 (CV%) Interindividual variability
of IC50
53.1 (34.2) 56.3 (33.4)
Proportional
residual
error (%)
.20 (19.3) .20 (19.3)
CV indicates coefﬁcient of variation; RSE, relative standard error.
* Maximum inhibition could not be estimated based on observed data
and therefore was ﬁxed to 1. Hill coefﬁcient was estimated close to 1 and
was ﬁxed to 1 in the ﬁnal parameter estimation.
y The base model is the ﬁnal model, because none of the evaluated
covariates met the criteria for inclusion in the pharmacodynamic model.
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Figure 2. Interpatient variability in IMPDH activity in PMNCs on day þ21. Concentration-response of IMPDH activity by total MPA (A) and unbound MPA (B) plasma
concentrations. Time course of IMPDH activity and total MPA concentration (mean  SD) (C). Percentage of IMPDH activity (mean  SD) vs. total MPA corrected for
baseline (ie, predose) values (D).
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dynamic model accurately predicted the observed MPA
pharmacokinetics and IMPDH activity in a separate cohort of
HCT participants. For the population prediction, theMPE% for
total MPA, unbound MPA, total MPAG, and IMPDH activity
were 28.9%, 10.6%, 27.1%, and e1.85%, respectively. For indi-
vidual Bayesian predictions, MPE% for total MPA, unbound
MPA, total MPAG, and IMPDH activity were 4.85%,e2.0%, .4%,
and e.97%, respectively. As shown in Supplemental Figure 6,
most validation data fall within the 95% conﬁdence interval
of the predicted values that were derived from the
pharmacokinetic-dynamic parameters estimated from the
development dataset.
Pharmacodynamic Relationships
We also sought to evaluate if clinical outcomes could be
predicted by the day þ21 IMPDH AUEC. The analysis was
adjusted for Kahl relapse risk category, female donor to male
recipient, and donor type (unrelated versus related). As
shown in Table 4, Figure 3, and Supplemental Figure 7,
day þ21 IMPDH AUEC was associated with CMV reactivation
(P¼ .003), nonrelapsemortality (P¼ .04), and overall survival
(P ¼ .03).
DISCUSSION
The translational relevance of this work is that we created
a pharmacokinetic-dynamic model that characterizes the
relationship between IMPDH activity with plasma MPA
concentrations after oral MMF administration in non-
myeloablative HCT patients. Our key results are as follows:
(1) weight-based dosing of MMF results in considerable
interpatient variability in the inhibition of IMPDH activity,(2) a previous MPA population pharmacokinetic model in
HCT recipients has been validated [6], and (3) a population
pharmacokinetic-dynamic model of MPA concentrations
with IMPDH activity has been developed and validated. No
clinical covariates were found for the pharmacodynamic
parameters (Supplemental Figure 5), indicating that IMPDH
Table 4
Association of Day þ21 IMPDH AUEC with HCT Outcomes
Events* Odds Ratio/
Hazard Ratioy
(95% Conﬁdence
Interval)
P
Day þ28 T cell chimerism  95% 23 .96 (.4-2.6) .96
Grades II-IV acute GVHD 33 .72 (.4-1.3) .26
Grades III-IV acute GVHD 4 .13 (.0-1.0) .05
Extensive chronic GVHD 30 1.38 (.7-2.9) .38
Relapse 10 .95 (.3-3.2) .93
CMV reactivation 20 .29 (.1-.7) .003
Nonrelapse mortality 9 .23 (.1-1.0) .04
Overall mortality 17 .40 (.2-.9) .03
* Events on or after day þ26.
y Day þ28 T cell chimerism analyzed as binary endpoint (odds ratio), and
all others as time-to-event endpoint (hazard ratio). Odds ratio and hazard
ratio are effects per doubling of IMPDH AUEC. All analyses adjusted for Kahl
relapse risk category (low, standard, high), donorerecipient gender (female
to male, other), and donor (related, unrelated).
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research is needed to explain pharmacodynamic variability.
IMPDH AUEC on day þ21 was associated with CMV reac-
tivation, nonrelapse mortality, and overall mortality
(Table 4). These ﬁndings should be conﬁrmed in a larger
patient population, with the long-term goal of using IMPDH
activity in PMNC as a predictive biomarker to improve
survival.Figure 3. Association of IMPDH AUEC (pmol  106 cells) with acute GVHD (A), CMV re
receiving an unrelated donor graft. Only events on or after day þ26 are included.The immunosuppressant MMF is an integral component
of postgrafting immunosuppression after HCT. HCT re-
cipients receiving MMF dosed by body weight have varying
clinical outcomes [21]. We recently constructed MPA popu-
lation pharmacokinetic models after intravenous MMF [5] or
oral MMF [6] administration that revealed considerable IIV in
MPA pharmacokinetics. We validated this pharmacokinetic
model and reﬁned it by adding concentration-time data of
unbound MPA and total MPAG. Oral MMF dosed based on
body weight still results in considerable interpatient vari-
ability in ex vivo IMPDH activity in PMNCs isolated from
participants receiving the same 15-mg/kg dose of oral MMF
(Figures 2 and 4). An inhibitory Emax model adequately
described the inhibition of IMPDH activity in PMNCs byMPA.
The IIV of the pharmacodynamic parameters varied from
27.3% to 56.3% (Table 3). This IIV is greater than the IIV of
many pharmacokinetic parameters with the notable excep-
tion of the IIV of the volume estimates, which range from 47%
to 86.4% (Table 2). The large IIV in the volume estimates
could be attributed to the inability to accurately characterize
the maximumMPA concentration due to the use of a limited
sampling schedule, which is a necessity in this patient pop-
ulation treated in the ambulatory clinic.
We hypothesized that estimating its drug-speciﬁc phar-
macodynamics (IMPDH activity in PMNCs) could be a
predictive measure of an individual’s response to MMF.
Determining IMPDH activity may provide a directactivation (B), nonrelapse mortality (C), and overall mortality (D) in 45 patients
Figure 4. Visual representation of IMPDH AUEC (gray area, in units of
pmol  106 cells) after a single dose of MMF at steady state (A) and distri-
bution of IMPDH AUEC in all patients (B).
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immunosuppression and subsequent clinical efﬁcacy and
toxicity. Notably, on dayþ21, the PMNCs can be derived from
the recipient, a mixture of donor and recipient cells, or solely
donor cells. The dayþ28 donor T cell chimerism is presented
in Table 1; most patients had >95% T cell chimerism. Vari-
ability in the cellular uptake and activation of MPA in PMNCs
may account for this differential cellular sensitivity. Notably,
concomitant calcineurin inhibitor and graft source were not
associated with the IC50 and Emax of IMPDH inhibition, sug-
gesting these factors do not inﬂuence sensitivity to MMF
(Supplemental Figure 5).
To our knowledge, this publication is the ﬁrst to evaluate the
association of IMPDH activity after MMF administration in
nonmyeloablative HCT recipients. Within HCT recipients, Lav-
erdière et al. [11] characterized IMPDH activity in 19 HCT re-
cipients whose conditioning regimen, graft source, and MMF
regimen were not detailed. These investigators reported a 5.3-
fold variability in IMPDH activity; our results show a 10-fold
variability in IMPDH activity (Figure 2A and B) and 6-foldvariability in IMPDH AUEC (Figure 4B). Although we developed
a validated LC/MS method to quantitate IMPDH activity, we
could not quantitate IMPDH activity on day þ2 because of
extremely low white blood cell counts, predominantly due to
ﬂudarabine/total body irradiation conditioning.
In conclusion, we have shown that adequate number of
PMNC can be isolated from HCT recipients on day þ21 to
quantitate XMP, and thus IMPDH activity, using our highly
sensitive assay. We presented an integrated population-
based model of total MPA, unbound MPA, and total MPAG
plasma concentrations and the associated degree of immu-
nosuppression, as quantiﬁed by IMPDH activity in PMNCs.
The ﬁnal model captured the central tendencies and IIV well;
there were, however, no clinical covariates associated with
the pharmacodynamic parameters. Such amodel provides an
approach toward individualized oral MMF dosing and a ﬁrm
rationale for further studies investigating whether dosing
MMF on the basis of IMPDH activity can improve clinical
outcomes. Subsequent translational studies will be necessary
to evaluate whether IMPDH activity after MPA provides a
novel biomarker to predict an individual’s sensitivity and
response toMMF, with the long-range goal of individualizing
postgrafting immunosuppression and/or MMF doses to
improve the efﬁcacy and/or decrease the toxicity of non-
myeloablative HCT.ACKNOWLEDGMENTS
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